JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Protagonist Therapeutics (PTGX) and raises the price target from $42 to $45.
May 08, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities raises Protagonist Therapeutics' price target from $42 to $45, maintaining a Market Outperform rating.
The increase in price target by JMP Securities reflects a positive outlook on Protagonist Therapeutics, likely due to strong company fundamentals or positive developments. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100